<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00583609</url>
  </required_header>
  <id_info>
    <org_study_id>851-PP-03</org_study_id>
    <nct_id>NCT00583609</nct_id>
  </id_info>
  <brief_title>A Pilot Study of a New PEG3350 Dose Formulation For Use in Constipated Children</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Braintree Laboratories</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Braintree Laboratories</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the patient acceptance of a new PEG3350 dose formulation in children currently
      treated with PEG3350 powder for treatment of constipation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy will be measured by analysis of patient self reported bowel movement (BM) data</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PEG3350</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PEG3350</intervention_name>
    <description>PEG3350</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female constipated outpatients between the ages of 4 and 16

          -  Currently taking a dose of PEG 3350 powder up to a maximum of 17g per day that has
             been consistent for at least 4 weeks, or if less than 4 weeks, the investigator
             testifies that the patient is stable

          -  Current treatment is considered successful - defined as greater than 2 bowel movements
             per week with no accidents

          -  Are otherwise in good health, as judged by a physical examination

          -  If female and of childbearing potential, patient must be using oral contraceptives,
             depot contraceptives, intrauterine device, or testifies that she is monogamous with a
             vasectomized partner, or practices abstinence and will continue to do so for the
             duration of the study

          -  In the investigator's judgment, patient or guardian is mentally competent to sign an
             instrument of informed consent

        Exclusion Criteria:

          -  Patients who are impacted at baseline exam

          -  Patients with known or suspected perforation or obstruction

          -  Patients with a history of gastric retention, inflammatory bowel disease, bowel
             resection, or colostomy

          -  Patients with a known history of organic cause for their constipation

          -  Patients currently using medications known to cause constipation (these include
             opiates, antidepressants, SSRI's, antimotility agents and anticholinergics)

          -  Patients who are breastfeeding, pregnant, or intend to become pregnant during the
             study

          -  Female patients of childbearing potential who refuse a pregnancy test

          -  Patients who, in the opinion of the investigator, should not be included in the study
             for any reason, including inability to follow study procedure

          -  Patients with known allergy to PEG or PEG containing medications

          -  Patients who, within the past 30 days have participated in an investigational clinical
             study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John McGowan</last_name>
    <role>Study Director</role>
    <affiliation>Braintree Laboratories, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2007</study_first_submitted>
  <study_first_submitted_qc>December 28, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2007</study_first_posted>
  <disposition_first_submitted>September 24, 2009</disposition_first_submitted>
  <disposition_first_submitted_qc>September 24, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 28, 2009</disposition_first_posted>
  <last_update_submitted>September 24, 2009</last_update_submitted>
  <last_update_submitted_qc>September 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 28, 2009</last_update_posted>
  <responsible_party>
    <name_title>John McGowan, Clinical Operations Manager</name_title>
    <organization>Braintree Laboratories, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polyethylene glycol 3350</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

